Revance
Estados Unidos
clásico
Sitio web: http://www.revance.com
Categorías industriales
- Inyectables: Toxinas botulínicas
- Inyectables: Rellenos
- Gestión de la práctica: Servicios de negocios - Softwares - Hardware - Diseño web - servicios de internet
Perfil de la empresa
Revance® is creating a new neuromodulator category, and true innovation in aesthetic medicine and therapeutic specialties with their lead investigational product candidate, DaxibotulinumtoxinA for Injection (DAXI).
In the Phase 3 SAKURA clinical trials, DAXI achieved unrivalled efficacy, including a median 24-week duration of effect in treating glabellar lines. Revance’s open-label, long-term safety study, SAKURA 3, was the largest clinical program of an aesthetic neuromodulator, and included nearly 2,700 patients and more than 3,800 treatments.
Revance anticipates commercial launch in 2020 upon FDA approval.
In the Phase 3 SAKURA clinical trials, DAXI achieved unrivalled efficacy, including a median 24-week duration of effect in treating glabellar lines. Revance’s open-label, long-term safety study, SAKURA 3, was the largest clinical program of an aesthetic neuromodulator, and included nearly 2,700 patients and more than 3,800 treatments.
Revance anticipates commercial launch in 2020 upon FDA approval.